### Development and validation of risk prediction models for childhood, teenage and young

### adult cancers: research protocol and statistical analysis plan

Defne Saatci<sup>1</sup>, Anthony Harnden<sup>1</sup>, Julia Hippisley-Cox<sup>1</sup>

<sup>1</sup> Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

### Abstract

### Background

Childhood, teenage and young adult (CTYA, 0-24 years) cancers are rare and diverse, making timely diagnosis challenging. Studies based on adult cancers suggest that the development and integration of clinical decision tools in primary care aid earlier cancer detection, yet, these have not been explored for CTYA cancers.

Aim

To develop and validate a primary care-based risk prediction tool to identify CTYA who are at increased risk of cancer.

### Methods and analysis

Using the QResearch Database, a nationally representative primary care database, we will generate an open cohort of children, teenagers and young adults (0-24 years) who were registered with a GP between 1<sup>st</sup> January 1998 and 31<sup>st</sup> December 2019. CTYA will be followed up from the date at which the first cancer-relevant symptom is recorded in the records (index date) until the date of cancer diagnosis/6-months, whichever comes first. Candidate variables will include symptoms, signs, blood test results and demographic factors. Model derivation will include two approaches, Cox regression and logistic regression. Apparent performance of the derived model will be explored and subsequently internally-externally cross-validated to investigate performance heterogeneity and geographical transportability.

#### Introduction

Childhood and teenage cancer ranks as the 6<sup>th</sup> leading cause of total cancer burden worldwide and is associated with significant long-term morbidity<sup>1</sup>. Cancer is the commonest cause of mortality by disease among children and young people in the United Kingdom (UK)<sup>2</sup>. Delayed cancer detection is a known contributing factor<sup>3</sup>, with presentation at advanced stages recognised to reduce survival<sup>4</sup>. The UK has longer time-to-diagnosis across childhood cancers compared to other high-income countries<sup>5,6</sup>, as well as higher mortality rates across teenage and young adult cancers<sup>7</sup>. This is an ongoing concern for young people with cancer, who, in a recent national survey, highlighted early diagnosis research as one of their top ten research priorities<sup>8</sup>. This collectively highlights a clear health challenge and there is a pressing need to improve early detection of these cancers in the UK. Indeed, this is in line with the National Health Service (NHS) Long Term Plan (2019)<sup>9</sup>, UK Cancer Reform Strategy (2015)<sup>10</sup> and Childhood Cancer and Leukaemia Group (CCLG) Strategic Plan (2020)<sup>11</sup>.

The non-specific presentation and relative rarity of childhood, adolescent and young adult cancers (CTYA) pose difficult diagnostic challenges to clinicians<sup>12</sup> and increase the possibility of delays. This is particularly relevant to general practitioners (GPs) who encounter CTYA cancer patients at the earliest stages of the disease. National awareness initiatives, such as HEADSMART<sup>5</sup>, have been employed to address this challenge in the UK and although this initiative contributed to substantial improvements in diagnostic intervals in central nervous system (CNS) tumours, the national time-to-diagnosis target of 4 weeks has not been reached for all age groups<sup>13</sup>. Furthermore, GPs remain unconfident in diagnosing childhood cancers even after taking part in this initiative<sup>14</sup>. Similarly, recent findings of the "Accelerate, Coordinate, Evaluate" (ACE) programme demonstrated ongoing delays in referrals and cancer diagnosis in TYA<sup>15</sup>. Clearly, novel approaches need to be explored to supplement current pathways.

Computer-based clinical decision tools (CDTs) are increasingly being used in clinical settings, supporting medical decision-making where challenges such as diagnostic uncertainty are present<sup>16</sup>. Overall, CDTs have been reported to reduce diagnostic errors<sup>17</sup>, improve clinical practice and patient care<sup>17</sup>. In primary care settings, recent evidence suggests that technology-based CDTs provide the most successful interventions in reducing diagnostic inaccuracies<sup>18</sup>. The potential for CDTs in cancer diagnosis have been highlighted as an "area of extraordinary opportunity", with promising developments seen in several adult cancers<sup>19</sup>. A recent systematic review<sup>20</sup> has shown that these tools for cancer risk prediction have the potential to improve decision-making and clinical service outcomes, as well as one study showing reduction in time-to-diagnosis. Despite these advancements in adult cancers, however, CDTs have not been explored in CTYA cancers.

Accordingly, in this study, we plan to use QResearch Database, one of the largest GP electronic health record database in the UK, to explore ways to detect childhood and TYA cancers earlier by developing a novel GP-based risk prediction tool for CTYA cancers.

### **Methods and Analysis**

### Data sources and Study Population

### **Data Sources**

QResearch Database is a nationally representative primary care database consisting of over 35 million anonymised health records from approximately 1300 general practices (GPs) in England (~20% UK population)<sup>21,22</sup>. Records consist of patient-level demographic information (i.e., year-of-birth, sex, self-assigned ethnicity), as well as clinical information, including cancer diagnoses and clinical presentations. Primary care records are linked to hospital admission, civil registration and the National Cancer Registry data, where linkage is based on an individual patient's anonymized NHS number. This number is valid and complete in 99.8% of primary care/civil registry data and 98% of hospital admissions data<sup>22</sup>.

### **Study Population**

Model development and validation will use an open cohort of children, teenagers and young adults (from birth up to 25 years) who were registered with a GP within QResearch Database between 1<sup>st</sup> January 1998 and 31<sup>st</sup> December 2019.

Cohort entry will be the latest of date of registration with the practice plus 1 year, date on which the practice computer system was installed plus 1 year, and the study start date (1 January 1998) and for those who have cancer-relevant clinical features the first date in which the clinical feature was recorded. Exit from the cohort will be the earliest of 6 months following study entry date, 6 months following first recorded cancer-relevant symptom, or cancer diagnosis. Analyses will be restricted to CTYA who had a cancer diagnosis within 6 months or CTYA who had at least 6 months follow-up.

Cases will be defined as the commonest non-skin cancer diagnoses in this age group<sup>23</sup> and will be categorised into subtypes according to the International Classification for Childhood Cancers (third edition, ICCC-3)<sup>24</sup>: 1) Leukaemias and myelodysplastic diseases, 2) lymphomas and reticuloendothelial neoplasms, 3) central nervous system and intraspinal tumours, 4) soft tissue and bone sarcomas, 5) abdominal tumours (renal tumours, neuroblastomas, hepatoblastomas) and 6) germ cell, trophoblastic and other gonadal tumours. Cases and their date of diagnosis will be identified through the National Cancer Registry. Cases with a diagnosis prior to study start date were excluded, as were those with the following pre-existing conditions linked to cancer: Down's Syndrome, neurofibromatosis type I and II, ataxia telangiectasia, tuberous sclerosis, and Li Fraumeni <sup>25-29</sup>. Incidence rates will be calculated for childhood (0-14 years) and TYA (15-24 years) and compared to available national incidence rates.

## **Outcome of Interest**

The outcome of interest will be a diagnosis of the selected CTYA cancers within/at 6 months from presentation:

- 1. CTYA blood cancers (0-24 years): Any leukaemia/lymphoma diagnosis
- 2. CTYA solid cancers (0-24 years): Any CNS/sarcoma/abdominal tumour/gonadal germinal tumour diagnosis

Any CTYA who has a cancer diagnosis prior to cohort entry or after cohort exit will be excluded.

## Selection of Clinical Features and Risk Factors (Candidate Predictor Variables)

Table 1 details all identified candidate predictor variables for model development. Cancerassociated clinical features in CTYA will be selected through previously published evidence available<sup>30-33</sup>. These clinical features (includes symptoms, signs and blood test results) will be identified through QResearch Database and results determined to be incorrect/outliers by the clinical team will be excluded. All blood test results will be categorised into normal and abnormal according to nationally available laboratory cut-off values<sup>34</sup>. Any clinical feature before cohort entry or after cohort exit will be excluded.

Record of sociodemographic risk factors on the study entry date will be used for data extraction. Ethnicity will be defined as self- or parent-reported ethnicity on primary care health records. Ethnic groups are recorded based on the 2011 Census of England and Wales in 2 broad categories (White, Other)<sup>35</sup>. Level of deprivation will be assessed through the Townsend deprivation score which is an area-level continuous score based on an individual's postcode; factors that included unemployment, non–car ownership, non–home ownership, and household overcrowding, are measured for a given area of approximately 120 households, via the 2011 Census of England and Wales and combined to give a Townsend score for that area, with the first quintile representing the lowest deprivation level and the fifth quintile representing the highest deprivation level<sup>36</sup>.

	Variables	
Demographic	Age	
	Sex	
	Deprivation Level	
	Ethnicity	
Clinical Features	Organomegaly/abdominal mass	
	Lymphadenopathy	
	Fever	
	Limb pain	
	Joint pain	

Table 1. Candidate Predictor Variables for Model development

	Limp/abnormal gait		
	Bruising		
	Tiredness		
	Looks anaemic/pale		
	Abdominal pain		
	Rash		
	Abnormal skin lesions		
	Cough		
	Chest pain		
	Headache		
	Vomiting		
	Head/neck lump		
	Lump on body		
	Hemiparesis		
	Squint		
	Visual acuity problems		
	Seizures		
	Haematuria		
	Feels unwell		
	Constipation		
	Dizziness		
Blood Tests	Haemoglobin		
	White cell count (inc. differential count)		
	Platelet count		
	Mean Cell Volume		
	C-reactive protein		
	Erythrocyte sedimentation rate		
	Ferritin		
	Lactate Dehydrogenase		
	Alanine transaminase (ALT)		
	Bilirubin		
	Albumin		

## Sample Size Calculations

Sample size calculations were carried out using 'pmsampsize' on Stata<sup>37</sup>. We set our time point at 6 months and used 15% of the maximum permitted Cox-Snell R-squared (derived from Riley et al., 2020<sup>37</sup>) as there are no previous risk prediction models for its derivation. Cancer Research UK data were used to estimate incidence of cancers. We provide sample size calculations for the following cohorts: 1) blood cancers (leukaemias and lymphomas), 2) solid

cancers (CNS, renal and hepatic tumours, soft tissue and bone sarcomas and neuroblastomas) (Table 2).

Table 2. Sample size requirements for clinical prediction model development using Riley et al., 2020<sup>37</sup>

Cohort	R <sup>2</sup> <sub>cs</sub>	Parameters	Diagnosis Rate	Required	Events per
				Sample	predictor
				size	parameter
Blood cancers	0.00027	30	0.000089	999850	3
(0-24 years)			(89 per million)		
Solid Tumours	0.0003	30	0.0001	870818	3
(0-24 years)			(100 per million)		

Previous studies using QResearch have identified a cohort of ~5 million children and young adults<sup>38</sup>, with approximately 2 million children and 3 million teenagers and young adults. Altogether, this indicates that our study has sufficient sample size.

### Model Derivation

We will explore two modelling approaches for model derivation:

- 1. Cox proportional hazards model
- 2. Logistic regression model

First, a full model will be fitted using all candidate predictors in all imputed datasets and combined using Rubin's rules. Second, the pooled model will be used to select any categorical predictor with exponentiated coefficients >1.1 or <0.9 (at p<0.01) and any continuous predictors with significance of p<0.01. Third, these selected predictors will be used to refit the final model. This is to ensure both clinical and statistical magnitude of predictors are considered. Interactions between variables will be considered (based on a clinical plausibility) and interaction terms included within the model development process. Model coefficients will be combined, and in the case of Cox models with the baseline survival function, in order to calculate the linear predictor. Finally, model performance will be assessed through calculating the apparent discrimination, using Harrell's C-index if cox regression and area-under-the-curve if logistic regression, and calibration, using calibration-in-the-large, calibration slope and smoothed calibration plots.

For cox regression models, proportional hazard assumptions will be assessed using Schoenfeld residuals.

## Model Validation

The model derivation process will be validated using the internal-external cross validation approach<sup>39</sup>. This approach allows for the assessment of overall model performance as well as

potential transportability of the model to a 'distinct' population and takes advantage of the availability of data from different geographical locations within QResearch Database (up to 10 locations across England). The summary of this approach is as follows: first, one geographical region will be 'excluded' whilst the model is developed using all other available regions. Second, data from the 'excluded' geographical region will be used to assess model performance using the aforementioned performance measures. These two steps will be repeated for each geographical region. Finally, random effects meta-analysis using the Hartung-Knapp-Sidik-Jonkmann method<sup>40</sup> will be carried out to pool region-level performance measures and provide a pooled estimate of performance measures (i.e., discrimination and calibration).

## Missing Data and other Statistical Consideration

We anticipate that there will be missing data for deprivation level (Townsend Quintile), ethnicity and blood test values and we consider these variables under the missing at random assumption<sup>41</sup>. For categorical variables we will use multinomial logistic regression, for ordinal variables ordinal logistic regression for imputation. 5 imputations will be carried out to strike a balance between % missingness and computational efficiency. Model coefficients will be pooled in accordance with Rubin's rules. The imputation model will be inclusive of candidate variables and the outcome variable.

Any continuous candidate variable (e.g., age) will be assessed for nonlinearity and handled using fractional polynomials. Fractional polynomials will be fitted prior to imputation analyses. Clustering of participants within individual general practices will be accounted for using clustered standard errors.

## **Decision Curve Analysis**

To assess potential clinical utility, a decision curve analysis will be used to compare standard net clinical benefit (i.e., the trade-off between the benefits of true positives and harms of false positives) using developed models with a scenario where no model is used.

## Statistical Software

All analyses will be carried out using Stata (v17)<sup>42</sup>.

## Patient and Public Involvement

National charities were approached to identify patient representatives and currently two representative young people have volunteered to provide input in study design, interpretation and dissemination of results.

## Ethics and Dissemination

This project (OX94) has been approved by the QResearch scientific committee. The QResearch database annually obtains ethical approval from the East Midlands-Derby Research Ethics Committee (REC reference 18/EM/0400).

# **References**

Collaborators GBDCC. The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. *Lancet Oncol* 2019; **20**(9): 1211-25.
Patel V.

https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/childhoodinfantandperinatalmortalityinenglandandwales/2017. 2019.

3. Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. *Br J Cancer* 2015; **112 Suppl 1**: S92-107.

4. Youlden DR, Frazier AL, Gupta S, et al. Stage at diagnosis for childhood solid cancers in Australia: A population-based study. *Cancer Epidemiol* 2019; **59**: 208-14.

5. HeadSMART. HeadSmart Be Brain Tumour Aware. 2013.

6. Ahrensberg JM, Olesen F, Hansen RP, Schroder H, Vedsted P. Childhood cancer and factors related to prolonged diagnostic intervals: a Danish population-based study. *Br J Cancer* 2013; **108**(6): 1280-7.

7. <u>http://www.ncin.org.uk/view?rid=3295</u>.

8. Aldiss S, Fern LA, Phillips RS, et al. Research priorities for young people with cancer: a UK priority setting partnership with the James Lind Alliance. *BMJ Open* 2019; **9**(8): e028119.

9. <u>https://www.longtermplan.nhs.uk/online-version/chapter-3-further-progress-on-care-</u> guality-and-outcomes/a-strong-start-in-life-for-children-and-young-people/children-and-youngpeople-with-cancer/.

10. Kumar H. obotCSTSoICSfE.

https://www.cancerresearchuk.org/sites/default/files/statement\_of\_intent\_-final\_0.pdf

11. <u>https://www.cclg.org.uk/write/MediaUploads/About%20CCLG/CCLG\_Strategic\_Plan\_2018-</u>2025.pdf.

12. Dang-Tan T, Franco EL. Diagnosis delays in childhood cancer: a review. *Cancer* 2007; **110**(4): 703-13.

13. Shanmugavadivel D, Liu JF, Murphy L, Wilne S, Walker D, HeadSmart. Accelerating diagnosis for childhood brain tumours: an analysis of the HeadSmart UK population data. *Arch Dis Child* 2020; **105**(4): 355-62.

14. <u>https://www.health.org.uk/sites/default/files/CtGtCC\_HeadSmart\_report.pdf</u>.

15. Dommett RM, Pring H, Cargill J, et al. Achieving a timely diagnosis for teenagers and young adults with cancer: the ACE "too young to get cancer?" study. *BMC Cancer* 2019; **19**(1): 616.

16. Kawamoto K, Jacobs J, Welch BM, et al. Clinical information system services and capabilities desired for scalable, standards-based, service-oriented decision support: consensus assessment of the Health Level 7 clinical decision support Work Group. *AMIA Annu Symp Proc* 2012; **2012**: 446-55.

Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. *NPJ Digit Med* 2020; 3: 17.

18. McDonald KM, Matesic B, Contopoulos-Ioannidis DG, et al. Patient safety strategies targeted at diagnostic errors: a systematic review. *Ann Intern Med* 2013; **158**(5 Pt 2): 381-9.

19. Usher-Smith J, Emery J, Hamilton W, Griffin SJ, Walter FM. Risk prediction tools for cancer in primary care. *Br J Cancer* 2015; **113**(12): 1645-50.

20. Chima S, Reece JC, Milley K, Milton S, McIntosh JG, Emery JD. Decision support tools to improve cancer diagnostic decision making in primary care: a systematic review. *Br J Gen Pract* 2019; **69**(689): e809-e18.

21. Hippisley-Cox J, Stables D, Pringle M. QRESEARCH: a new general practice database for research. *Inform Prim Care* 2004; **12**(1): 49-50.

22. <u>www.qresearch.org</u>. (accessed 21/12 2022).

23. <u>https://www.cancerresearchuk.org/health-professional/cancer-statistics/</u>.

24. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. *Cancer* 2005; **103**(7): 1457-67.

25. Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. *Oncologist* 2009; **14**(2): 164-73.

26. Campian J, Gutmann DH. CNS Tumors in Neurofibromatosis. *J Clin Oncol* 2017; **35**(21): 2378-85.

27. Reiman A, Srinivasan V, Barone G, et al. Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. *Br J Cancer* 2011; **105**(4): 586-91.

Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. *Lancet* 2008; **372**(9639): 657-68.
Kratz CP, Achatz MI, Brugieres L, et al. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. *Clin Cancer Res* 2017; **23**(11): e38-e45.

30. Dommett RM, Redaniel MT, Stevens MC, Hamilton W, Martin RM. Features of childhood cancer in primary care: a population-based nested case-control study. *Br J Cancer* 2012; **106**(5): 982-7.

31. Dommett RM, Redaniel MT, Stevens MC, Hamilton W, Martin RM. Features of cancer in teenagers and young adults in primary care: a population-based nested case-control study. *Br J Cancer* 2013; **108**(11): 2329-33.

32. Wilne S, Collier J, Kennedy C, Koller K, Grundy R, Walker D. Presentation of childhood CNS tumours: a systematic review and meta-analysis. *Lancet Oncol* 2007; **8**(8): 685-95.

33. Clarke RT, Van den Bruel A, Bankhead C, Mitchell CD, Phillips B, Thompson MJ. Clinical presentation of childhood leukaemia: a systematic review and meta-analysis. *Arch Dis Child* 2016; **101**(10): 894-901.

34. RCPCH Laboratory Reference Ranges. 2016.

https://www.rcpch.ac.uk/sites/default/files/rcpch/HTWQv8.7/Reference%20ranges%20Feb%2018% 20FINAL.pdf (accessed 31/05 2024).

35.

https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity/articles/2011ce nsusanalysisethnicityandreligionofthenonukbornpopulationinenglandandwales/2015-06-18.

36. Townsend P DN. Inequalities in Health: The Black Report.: Dept of Health and Social Security; 1982.

37. Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing a clinical prediction model. *BMJ* 2020; **368**: m441.

38. Saatci D, Oke J, Harnden A, Hippisley-Cox J. Childhood, teenage and young adult cancer diagnosis during the first wave of the COVID-19 pandemic: a population-based observational cohort study in England. *Arch Dis Child* 2022; **107**(8): 740-6.

39. Steyerberg EW, Harrell FE, Jr. Prediction models need appropriate internal, internal-external, and external validation. *J Clin Epidemiol* 2016; **69**: 245-7.

40. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. *BMC Med Res Methodol* 2014; **14**: 25.

41. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ* 2009; **338**: b2393.

42. StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC.; 2021.